Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Hompesch

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Diabetes, Obesity & Metabolism|August 11, 2021
Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy malesMarcus Hompesch, Aleksandra Hawryluk, Moises Hernandez, et al.
Diabetes Technology & Therapeutics|December 6, 2011
Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Endocrinology, Diabetes & Metabolism|April 15, 2021
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patientsBrian Baker, Barbara Schaeffler, Joe Hirman, et al.
Diabetes Technology & Therapeutics|July 1, 2011
Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteersLinda Morrow, Douglas B Muchmore, Elizabeth A Ludington, et al.
Clinical Therapeutics|February 11, 2014
Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitusMarcus Hompesch, Linda Morrow, Elaine Watkins, et al.
Endocrinology, Diabetes & Metabolism|April 7, 2022
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASHAdrian Vilalta, Julio A Gutiérrez, SuZanne Chaves, et al.
Diabetes Care|October 9, 2012
Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidaseLinda Morrow, Douglas B Muchmore, Marcus Hompesch, et al.
Diabetes Technology & Therapeutics|June 23, 2009
Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetesMarcus Hompesch, Alexa Kollmeier, Klaus Rave, et al.
Diabetes, Obesity & Metabolism|August 6, 2025
GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trialChristine L N Bryant, Kevin Colbert, Marcus Hompesch, et al.
The Journal of Clinical Endocrinology and Metabolism|June 23, 2012
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy malesEnsio Norjavaara, Hans Ericsson, Folke Sjöberg, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|August 11, 2021
Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy malesMarcus Hompesch, Aleksandra Hawryluk, Moises Hernandez, et al.
Diabetes Technology & Therapeutics|December 6, 2011
Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Endocrinology, Diabetes & Metabolism|April 15, 2021
Tolerability of eptinezumab in overweight, obese or type 1 diabetes patientsBrian Baker, Barbara Schaeffler, Joe Hirman, et al.
Diabetes Technology & Therapeutics|July 1, 2011
Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteersLinda Morrow, Douglas B Muchmore, Elizabeth A Ludington, et al.
Clinical Therapeutics|February 11, 2014
Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitusMarcus Hompesch, Linda Morrow, Elaine Watkins, et al.
Endocrinology, Diabetes & Metabolism|April 7, 2022
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASHAdrian Vilalta, Julio A Gutiérrez, SuZanne Chaves, et al.
Diabetes Care|October 9, 2012
Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidaseLinda Morrow, Douglas B Muchmore, Marcus Hompesch, et al.
Diabetes Technology & Therapeutics|June 23, 2009
Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetesMarcus Hompesch, Alexa Kollmeier, Klaus Rave, et al.
Diabetes, Obesity & Metabolism|August 6, 2025
GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trialChristine L N Bryant, Kevin Colbert, Marcus Hompesch, et al.
The Journal of Clinical Endocrinology and Metabolism|June 23, 2012
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy malesEnsio Norjavaara, Hans Ericsson, Folke Sjöberg, et al.
Pageof 6